Kintara Therapeutics, Inc. Price Today
Kintara Therapeutics, Inc.
KTRA
Healthcare
$5.25M
💰
Market Cap
0
💸
Price to Earnings
$-5.2
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Hold Consensus
Buy |
0 |
Strong Buy |
0 |
Hold |
3 |
Sell |
1 |
Strong Sell |
2 |
KTRA Price Forecast Target
0.1 👉 0 +0%
KTRA EPS Forecast
-5.2 👉 -0.4 +-93%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
0.2% - Insiders
0.6% - Institutions
99.2% - Public
Major Fund Holders
-
💰 Acadian Asset Management. LLC $17,186.0
-
💰 Geode Capital Management, LLC $5,805.0
-
💰 Nantahala Capital Management, LLC $5,923.0
-
💰 Stratos Wealth Partners, Ltd. $2,689.0
-
💰 Vanguard Group Inc $1,675.0
Stock Ideas
Ken Fisher Portfolio
Ken Fisher is a prominent American investment analyst, author, and the founder of Fisher Investments, a global investment firm managing billions of dollars in assets for individual and institutional clients. As a highly successful investor and fina…
Louis Bacon Portfolio
Louis Bacon is the founder of Moore Capital Management and is one of the famous traders of the past two decades. His personal wealth is more than $1.5 Billion and had more than $15 Billion in AUM. He has an MBA degree from Columbia Business School.
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
Carl Icahn Portfolio
With a staggering net worth exceeding $16 billion, Icahn has made a lasting impact on the stock market as the founder and manager of Icahn Enterprises. Known as a 'corporate raider,' Icahn has gained fame for his relentless pursuit of undervalued co…📮FAQ
Some Frequently Asked Questions.
The Kintara Therapeutics, Inc. industry is Biotechnology
The Kintara Therapeutics, Inc. sector is Healthcare
The Kintara Therapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -0.4
The Kintara Therapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Kintara Therapeutics, Inc. is $5.25M
There are total of 39026188 float shares with 0.6% held by Institutions and 0.2% held by insiders
The MKintara Therapeutics, Inc. forecasted Earnings per Share EPS is $-0.4
The Kintara Therapeutics, Inc. Earnings per Share EPS is -5.2
The Kintara Therapeutics, Inc. company has $0 gross profits with 0 profit margins
The Kintara Therapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Kintara Therapeutics, Inc. Revenue is $0 with 0 revenue growth
The price target for Kintara Therapeutics, Inc. stock is $0 for the high target and $0 for the low target
The consensus analyst recommendations for Kintara Therapeutics, Inc. is Hold, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Kintara Therapeutics, Inc. is Hold, with the following breakdown:
- Buy: 0
- Strong Buy: 0
- Hold: 3
- Sell: 1
- Strong Sell: 2
The Beta of Kintara Therapeutics, Inc. is 0.6
The dividend of Kintara Therapeutics, Inc. is $0
The dividend yield of Kintara Therapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Kintara Therapeutics, Inc. stock are
- Acadian Asset Management. LLC
- Geode Capital Management, LLC
- Nantahala Capital Management, LLC
- Stratos Wealth Partners, Ltd.
The Kintara Therapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0